9.2.8 Apr 28, 2015: Exactech Q1 Revenue $61.4 Million. Net Income Down 2% to $4.1 Million. Diluted EPS $0.29 vs. $0.30.
9.2.9 Apr 21, 2015: Stryker Reports First Quarter 2015 Results
9.2.10 Apr 09, 2015: Biomet Announces Third Quarter of Fiscal Year 2015 Financial Results
9.2.11 Mar 12, 2015: Cynata Therapeutics Commences Further Stage of Stem Cell Manufacturing Program
9.2.12 Mar 05, 2015: Amedica Reports Fourth Quarter and Full Year 2014 Financial Results
9.2.13 Feb 24, 2015: Zimmer Holdings Announces Quarterly Dividend for First Quarter of 2015
9.2.14 Feb 17, 2015: Exactech 2014 Revenue Up 5% to $248.4 Million, Net Income Up 7% to $16.5 Million, EPS $1.18
9.2.15 Feb 11, 2015: Stryker Declares a 13% Increase in Quarterly Dividend
9.2.16 Jan 29, 2015: Zimmer Holdings Reports Fourth Quarter and Full Year 2014 Financial Results
9.2.17 Jan 27, 2015: Stryker Reports 2014 Results
9.2.18 Jan 13, 2015: Stryker Provides 2014 Preliminary Results and Updates 2015 Foreign Exchange Outlook
9.2.19 Jan 06, 2015: Biomet Announces Second Quarter of Fiscal Year 2015 Financial Results
9.2.20 Dec 23, 2014: Repro Med Systems Announces Strong Results for Third Quarter Ended November 30, 2014
9.2.21 Dec 18, 2014: Amedica Announces Preliminary Q4 & FY 2014 Financial Results and Update on CASCADE Clinical Study
9.2.22 Dec 15, 2014: Zimmer Holdings Announces Quarterly Dividend for Fourth Quarter of 2014
9.2.23 Dec 04, 2014: Ra Pharmaceuticals Announces Presentation of Data Supporting Clinical Development of Novel Complement C5 Inhibitor at 2014 ASH Annual Meeting
9.2.24 Dec 03, 2014: Stryker Declares a 13% Increase in Quarterly Dividend
9.2.25 Nov 06, 2014: Amedica Reports Third Quarter 2014 Financial Results
9.2.26 Nov 06, 2014: Tornier Reports Third Quarter 2014 Results
9.2.27 Nov 05, 2014: Wright Medical Group, Inc. Reports 2014 Third Quarter Financial Results and Updated Guidance
9.2.28 Oct 23, 2014: Pfizer Wins SUTENT Patent Case In Delaware District Court
9.2.29 Oct 23, 2014: Zimmer Holdings Reports Third Quarter 2014 Financial Results
9.2.30 Oct 21, 2014: Exactech Q3 Revenue Up 4% to $57.9 Million; Net Income Down 6% to $3.0 Million Due to Currency Losses; Q3 Diluted EPS $0.21 vs. $0.23
9.2.31 Oct 16, 2014: Stryker Reports Third Quarter 2014 Results and 2014 Outlook
9.2.32 Oct 14, 2014: MOLOGEN AG presents EnanDIM: A new generation of immunomodulators
9.2.33 Oct 09, 2014: Biomet Announces First Quarter of Fiscal Year 2015 Financial Results
9.2.34 Aug 07, 2014: Amedica Reports Second Quarter 2014 Financial Results
9.2.35 Aug 05, 2014: Wright Medical Group, Inc. Reports 2014 Second Quarter Financial Results
9.3 Government and Public Interest
9.3.1 Jul 09, 2015: CMS proposes major initiative for hip and knee replacements
9.4 Legal And Regulatory
9.4.1 Jun 13, 2015: Wright Medical Technology Loses In Profemur R Hip Device Lawsuit
9.4.2 Dec 15, 2014: FDA Issues Warning Letter To Signal Medical
9.4.3 Oct 31, 2014: Biomet to Pay Over $6 Million to Resolve Whistleblower Claims That It Paid Kickbacks to Doctors
9.4.4 Oct 29, 2014: Biomet Companies to Pay Over $6 Million to Resolve False Claims Act Allegations Concerning Bone Growth Stimulators
9.5 Other Significant Developments
9.5.1 Mar 25, 2015: Mental Health Disorders Complicate Standards Readmissions
9.5.2 Mar 23, 2015: Federally Funded Project Establishes First National Database of Comprehensive Benchmarks for Total Hip and Knee Joint Replacement
9.5.3 Feb 10, 2015: Drug targeting Ebola virus protein VP24 shows promise in monkeys
9.5.4 Dec 23, 2014: Micron Products Announces Exclusive Agreement With New Era Orthopaedics
9.5.5 Nov 19, 2014: Oxford Performance Materials Receives Prestigious National Institutes Of Health Grant To Improve Treatment Of Infections Related To Artificial Hips, Knees And Other Implanted Devices
9.5.6 Aug 26, 2014: Zimmer Holdings Announces Quarterly Dividend for Third Quarter of 2014
9.5.7 Aug 21, 2014: Stryker Declares a $0.305 Quarterly Dividend July 2014
9.6 Product News
9.6.1 Aug 22, 2014: Advanced Hip Replacement Solutions from Zimmer Offer Once In A Lifetime Technology
9.7 Strategy And Business Planning
9.7.1 Apr 15, 2015: Motif Gains FDA Agreement To Enter Phase 3 Clinical Development With Iclaprim
9.7.2 Jan 20, 2015: InterMed Resources and Amedica Announce Agreement With HealthTrust
9.7.3 Jan 16, 2015: ZIMMER expands Irish Manufacturing presence
9.7.4 Jan 12, 2015: Amedica Announces Steps to Simplify Organization and Align Financial Objectives
9.7.5 Oct 30, 2014: Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing Of The Biomet Transaction
9.7.6 Sep 23, 2014: Stryker plans to construct new Innovation Centre in Cork
10.1 Research Methodology
10.1.2 Secondary Research
10.1.3 Primary Research
10.1.4 Market Modeling and Forecasting
10.1.5 Company Share Analysis
10.1.6 Distribution Share Analysis
10.2 Expert Panel
10.3 GlobalData Consulting
10.4 Contact Us
1.1 List of Tables
Table 1: Hip Reconstruction Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2007-2021
Table 2: Hip Reconstruction Market, North America, Category Comparison by Revenue ($m), USD Constant, 2007-2021
Table 3: Hip Reconstruction Market, North America, Revenue ($m), Historic, USD Constant, 2007-2014
Table 4: Hip Reconstruction Market, North America, Revenue ($m), Forecast, USD Constant, 2014-2021
Table 5: Hip Reconstruction Market, North America, Volume (Units), 2007-2021
Table 6: Hip Reconstruction Market, North America, Volume (Units), Historic, 2007-2014
Table 7: Hip Reconstruction Market, North America, Volume (Units), Forecast, 2014-2021
Table 8: Hip Reconstruction Market, North America, Company Share by Revenue ($m), USD Constant, 2014
North America Hip Reconstruction Market Outlook to 2021
GlobalData’s new report, North America Hip Reconstruction Market Outlook to 2021, provides key market data on the North America Hip Reconstruction market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market segments - Primary Hip Replacement, Revision Hip Replacement, Partial Hip Replacement and Hip Resurfacing.
The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country/region, information related to pipeline products, news and deals is available in the report.
The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.
The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.
Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Market size for Hip Reconstruction market segments - Primary Hip Replacement, Revision Hip Replacement, Partial Hip Replacement and Hip Resurfacing.
Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2007 to 2014 and forecast to 2021.
2014 company shares and distribution shares data for Hip Reconstruction market.
Global corporate-level profiles of key companies operating within the North America Hip Reconstruction market.
Key players covered include Zimmer Holdings, Inc., Stryker Corporation, DePuy Companies, Smith & Nephew Plc, Biomet, Inc. and Wright Medical Group, Inc.
Reasons to buy
Develop business strategies by identifying the key market segments poised for strong growth in the future.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.